Hikma updates expected launch of authorized generic XyremHikma now conservatively assumes it will launch its authorized generic on Jan. 1, 2023. FDA grants Glenmark tentative nod for generic EnstilarEnstilar foam had a market value of roughly $115.2 million for the 12-month period ending March 2022, according to IQVIA. FDA gives Lupin clearance for 2 generics The company received approval for Iloperidone tablets and pregabalin capsules. Alembic receives FDA nod for generic Abreva Docosanol cream 10% (OTC) had a market value of roughly $60 million for the 12 months ending December 2021, according to IQVIA. Xiromed intros progesterone injection The medication is the generic of progesterone injection, which is used to restore normal menstrual periods or treat abnormal bleeding due to low hormone levels. Advanz Pharma names new CEO Steffen Wagner joins Advanz from Stada, where he was a member of the Global Executive Committee and responsible for the European market. FDA gives Breckenridge tentative OK for generic Pradaxa Pradaxa had a market value of $455 million during the 12 months ending February 2022, according to industry data, the company said. Meitheal Pharmaceuticals joins AAM Meitheal primarily specializes in the development, manufacture, procurement and sale of generic injectable pharmaceuticals. Lundbeck names CFO, head of corporate functions Joerg Hornstein has been named chief financial officer and a member of Lundbeck’s executive management. Teva settles patent dispute with Lupin on generic Austedo Lupin will have a license to sell its generic product beginning April 2033 or earlier under certain circumstances. First Previous 86 87 88 89 90 Next Last
